A Phase II, Multicenter, Open-Label, Clinical And Pharmacokinetic Study Of Aplidin® As A 3 –Hour IV Infusion Every 2 Weeks, In Prostata ( EEUU ) .

Patente EEUU , Yondelis consigue Reforzar los efectos citotóxicos del Platinum .

Combined use of Yondelis and platinum antineoplastic compounds .
Publication number: US2007128201
Publication date: 2007-06-07
Inventor: D INCALCI MAURIZIO (IT); GIANNI LUCA (IT); GIAVAZZI RAFFAELLA (IT); MARTIN MARGARITA G (ES); JUDSON IAN (GB); DONAQUE JOSE M J (ES); SESSA CRISTIANA (CH)
Applicant: PHARMA MAR S A U (ES)
Classification: - international: A61K39/395; A61K31/282; A61K31/495; A61K31/555; A61K33/24; A61P35/00; A61K39/395; A61K31/28; A61K31/495; A61K31/555; A61K33/24; A61P35/00; - European: A61K31/282; A61K31/495; A61K31/555; A61K33/24
Application number: US20040558133 20040601
Priority number(s): GB20030012407 20030529; WO2004GB02319 20040601

Abstract of US2007128201 Yondelis can be used to mitigate resistance to and potentiate the cytotoxic effects of a platinum coordination complex anti-neoplastic agent in a human cancer patient.

Santander aumenta participación en Zeltia al 6 por ciento .

La EMEA analizará nuevamente a Acomplia la próxima semana .

La FDA revisa Acomplia para incluir información sobre comportamiento suicida .

BRCA2 y agresividad del cáncer de próstata .